A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 330 participants.

Also called NCT07373613

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 330 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07373613
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07373613. Randomized; double masking; primary purpose treatment. Start 2026-03-01 (anticipated); primary completion 2027-02-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
BR1400-1
Intervention (Drug)
BR1400-2
Intervention (Drug)
BR1400-3
Intervention (Drug)
BR1400-4
Intervention (Drug)
BR1400-5
Intervention (Drug)
BR1400-A
Intervention (Drug)
BR1400-B
Intervention (Drug)
BR1400-C
Lead sponsor
Boryung Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct07373613
Content hash
32a91c01d9d2f74d7e93516c65ab442c713ce452b89bd5c1a2c903736dd7a342